Back to results
US 2013/0260408 A1Published application
Fatty acid pattern analysis for predicting acute coronary syndrome
AssigneeIntegrated Health Leaders, LLC
InventorsGregory C. Shearer, James V. Pottala, William S. Harris
Life of this patent
Estimating the term…
Abstract
The present invention provides blood based methods for predicting risk of acute coronary syndrome in a subject.
Claims24
1-23. (canceled)
A method for predicting the risk of acute coronary syndrome (ACS) in a human subject, comprising:
- (a) measuring a combination of fatty acid markers in a fatty acid sample isolated from a blood component of a human subject, wherein the combination of the fatty acid markers, alone or together with the Framingham risk score (FRS) model, discriminates the ACS cases from controls better than the FRS model alone, the combination of the fatty acid markers comprising at least the following fatty acids:
- linoleic acid, gamma-linolenic acid, and docosahexaenoic acid (DHA);
- (b) comparing the amount of the fatty acid markers measured in the fatty acid sample to a control;
- and
- (c) predicting a risk of ACS based on the comparing in step (b), wherein the difference between the measured fatty acid markers and the control exceeding a statistical significance indicates a risk of ACS.
2 more elements
A method for predicting the risk of acute coronary syndrome (ACS) in a human subject, comprising:
- (a) measuring a combination of fatty acid markers in a fatty acid sample isolated from a blood component of a human subject, wherein the combination of the fatty acid markers, alone or together with the Framingham risk score (FRS) model, discriminates the ACS cases from controls better than the FRS model alone, the combination of the fatty acid markers comprising three or more of the following fatty acids:
- linoleic acid, gamma-linolenic acid, docosahexaenoic acid, eicosapentaenoic acid, oleic acid, alpha-linolenic acid, n-3 docosapentaenoic acid, palmitic acid, stearic acid, elaidic acid, n-6 docosapentaenoic acid, docosatetraenoic acid, palmitoleic acid, arachidonic acid, and cis-11,14-eicosadienoic acid;
- (b) comparing the amount of fatty acid markers measured in the fatty acid sample to a control;
- and
- (c) predicting a risk of ACS based on the comparing in step (b), wherein the difference between the measured fatty acid markers and the control exceeding a statistical significance indicates a risk of ACS.
2 more elements
A method for predicting the risk of acute coronary syndrome (ACS) in a human subject, comprising:
- (a) measuring a combination of fatty acid markers in a fatty acid sample isolated from a blood component of a human subject, wherein the combination of the fatty acid markers, alone or together with the Framingham risk score (FRS) model, discriminates the ACS cases from controls better than the FRS model alone, the combination of the fatty acid markers comprising at least the following fatty acids:
- linoleic acid, alpha-linolenic acid, arachidonic acid, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA);
- (b) comparing the amount of fatty acid markers measured in the fatty acid sample to a control;
- and
- (c) predicting a risk of ACS based on the comparing in step (b), wherein the difference between the measured fatty acid markers and the control exceeding a statistical significance indicates a risk of ACS.
2 more elements
Dependencies are inferred from the claim text.